Trial Profile
Phase II Open Label Trial to Assess the Efficacy and the Imapct on QTcF of Continuous Oral BIBW 2992 at a Daily Dose of 50mg in Patients With Relapsed or Refractory Solid Tumours Including Patients With Brain Metastases and Those With Glioblastoma Not Amenable to Other Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Brain metastases; Glioblastoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 05 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Apr 2011 Planned end date changed from 1 Mar 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.
- 14 Feb 2011 Planned end date changed from 1 Jan 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.